Advanced Enzyme Technologies Limited has informed the Exchange regarding a press release dated August 02, 2025, titled "Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed is Press Release, titled "Quarterly Earnings Release dated August 02, 2025.".
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies reported strong Q1 FY26 results with consolidated revenue rising 20% year-on-year to ₹1,859 million, up from ₹1,545 million a year ago. EBITDA grew 10% to ₹564 million, though EBITDA margin contracted to 30% from 33% in Q1 FY25. Profit after tax (PAT) increased 16% YoY to ₹404 million, lifting EPS to ₹3.57 from ₹3.05. On a sequential basis, revenue grew 11%, EBITDA 24%, and PAT jumped 51% versus Q4 FY25. The Human Nutrition segment (66% of revenue) led growth at 21% YoY, Animal Nutrition surged 51%, while Bio-Processing declined 6%. Domestic sales grew 32% YoY and now contribute 53% of revenue. The company remains a zero-debt entity funded entirely through internal accruals.
Broadly positive for shareholders — top-line growth of 20%, double-digit PAT growth, and strong sequential momentum signal healthy demand, particularly in domestic and Asian markets. However, EBITDA margin compression from 33% to 30% YoY is a watch point, as it suggests rising costs may be eating into profitability despite robust revenue gains.